Brief: Crinetics Announces First Patient Randomized In Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine In Carcinoid Syndrome
20/11/2025 21:41
Nov 20 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O: CRINETICS ANNOUNCES FIRST PATIENT RANDOMIZED IN PIVOTAL PHASE 3 CAREFNDR TRIAL EVALUATING PALTUSOTINE IN CARCINOID SYNDROME Source text: ID:nGNX6znPmd Further company coverage: CRNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crinetics Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million